Mesenchymal Stem Cells for Treatment of CNS Injury by Azari, Michael F et al.
316 Current  Neuropharmacology, 2010, 8, 316-323   
  1570-159X/10 $55.00+.00  ©2010 Bentham Science Publishers Ltd. 
Mesenchymal Stem Cells for Treatment of CNS Injury 
Michael F. Azari
1,*, Louisa Mathias
1, Ezgi Ozturk
1, David S. Cram
1,  
Richard L. Boyd
1 and Steven Petratos
1,2 
1Monash Immunology and Stem Cell Laboratories, School of Biomedical Sciences, Faculty of Medicine, Monash   
University, Clayton, Vic. Australia; 
2Molecular Neuropathology and Experimental Neurology Laboratory, Health   
Innovations Research Institute (HIRi) and School of Medical Sciences, RMIT University, Bundoora, Vic. Australia 
Abstract: Brain and spinal cord injuries present significant therapeutic challenges. The treatments available for these 
conditions are largely ineffective, partly due to limitations in directly targeting the therapeutic agents to sites of pathology 
within the central nervous system (CNS). The use of stem cells to treat these conditions presents a novel therapeutic  
strategy. A variety of stem cell treatments have been examined in animal models of CNS trauma. Many of these studies 
have used stem cells as a cell-replacement strategy. These investigations have also highlighted the significant limitations 
of this approach. Another potential strategy for stem cell therapy utilises stem cells as a delivery mechanism for therapeutic 
molecules. This review surveys the literature relevant to the potential of mesenchymal stem cells for delivery of therapeutic 
agents in CNS trauma in humans. 
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INTRODUCTION 
  The therapeutic efficacy of a large variety of stem and 
progenitor cells has been assessed in experimental models of 
central nervous system (CNS) injury and disease. The cur-
rent status of stem cells in general for the treatment of CNS 
trauma has recently been reviewed [1-3]. This review fo-
cuses on the use of mesenchymal stem cells (MSCs) in par-
ticular, with or without genetic modification, for treatment of 
spinal cord injury (SCI) and traumatic brain injury (TBI). 
  Earlier transplantation studies employed stem cells in a 
cell-replacement paradigm. Embryonic stem cells (ESCs) 
were first used in SCI by McDonald et al. in 1999 [4]. In this 
study they demonstrated appropriate differentiation that was 
associated with improved functional recovery. Similarly, 
adult-derived neural stem cells (NSCs) have been used in 
combination with immunosuppression and growth factors to 
treat SCI [5]. These investigators showed enhanced survival 
and differentiation of NSCs into myelinating oligodendro-
cytes. NSCs exhibited enhanced survival and engraftment 
resulting in increased numbers of transplant-derived myeli-
nating oligodendrocytes in the spinal cord that correlated 
with electrophysiological evidence of regeneration through 
the lesion site. However, stem cells (particularly the more 
primitive ESCs) may differentiate into inappropriate cell 
types following transplantation, thereby resulting in tumour 
formation particularly following allogeneic transplantations 
[6]. Even the more differentiated NSCs, derived from ESCs, 
represent heterogenous cell populations and retain the poten-
tial for inducing tumours upon transplantation [6, 7]. Trans-
planted stem cells may also die as a result of the hostile   
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environment of the injured CNS tissue that potentiates en-
dogenous cell death exacerbating the inflammatory response 
thereby expanding the lesion volume. The viability of neural 
precursor cells (NPCs) for instance has been reported to be 
low particularly when grafted into chronic spinal cord le-
sions necessitating the concomitant administration of growth 
factors [5]. Furthermore, NSCs can cause inappropriate 
sprouting and give rise to enhanced pain perception and allo-
dynia following SCI [8, 9]. The degree of allodynia caused 
by these grafts has also been correlated with the extent of 
their astrocytic differentiation [8]. However, it has recently 
been shown that pre-transplantation treatment of astrocytes 
(derived from glial restricted precursors) with BMP but not 
CNTF may limit the allodynia that is caused by grafting 
these cells into the injured CNS [10]. Given the propensity of 
NSCs to differentiate into glial cells following grafting into 
the adult injured CNS [11, 12], these cells could be expected 
to retain the potential to contribute to astrogliosis and the 
extension of the glial scar. Hence, it has become evident that 
simple transplantation of stem cells as a cell replacement 
strategy has limited utility in the treatment of CNS trauma. 
MESENCHYMAL STEM CELLS (MSCS) 
  In response to the challenges briefly outlined above, 
alternative transplantation strategies have emerged utilising 
adult stem cells, particularly MSCs and haematopoietic stem 
cells (HSCs), that have the intrinsic capacity to track to the 
site of the lesion within the CNS. Once at the site of the le-
sion, MSCs can secrete pro-survival factors such as insulin-
like growth factor (IGF) and brain derived neurotrophic fac-
tor (BDNF), vascular endothelial growth factor (VEGF), 
granulocyte-macrophage colony stimulating factor (GM-
CSF), fibroblast growth factor-2 (FGF2), and transforming 
growth factor-beta (TGF) [13-16]. In addition, these stem 
cells can be genetically modified to generate peptides or full-
length proteins of therapeutic potential such as autocrine MSCs for CNS Injury  Current Neuropharmacology, 2010, Vol. 8, No. 4    317 
factors that promote their own survival [17], as well as the 
survival or regeneration of neurons [18]. The two major stem 
cell types that can be isolated from blood and bone marrow 
are (i) HSCs, and (ii) MSCs also known as mesenchymal 
stromal cells or fibroblasts. MSCs were first recognised by 
Alexander Friedenstein and associates in the bone marrow 
by their ability to form fibroblastic colonies and differentiate 
into osteoblasts, chondrocytes and adipocytes [19]. MSCs 
can be easily harvested from a variety of tissues including 
the umbilical cord blood and adult adipose, bone marrow and 
skin tissues. They have also recently been isolated from ol-
factory tissue [20, 21]. In addition MSCs proliferate readily 
in culture and are amenable to genetic modification. There-
fore, they may be ideal candidates for development into ap-
propriate vehicles for delivery of therapeutic molecules. 
However, it is unclear, at present, whether MSCs isolated 
from different tissue sources have similar therapeutic poten-
tial and which source or isolation protocol is optimal for 
therapeutic purposes. A recent study for example has sug-
gested that while MSCs from both autologous and allogeneic 
sources resulted in functional improvement following SCI, 
autologous MSCs demonstrated greater benefit [22]. In addi-
tion, in an experimental SCI paradigm, intravenous admini-
stration of adipose tissue-derived MSCs that were differenti-
ated into oligodendrocyte precursor cells demonstrated mi-
gration of these cells to the site of the injury, as well as their 
partial neural differentiation which correlated with behav-
ioural recovery [23]. For a general review of MSCs and their 
role in health and disease refer to Uccelli et al. [24]. 
Beneficial Effects of MSC Transplantation 
  Experimental treatments of CNS trauma can be broadly 
grouped into the two distinct but interrelated strategies of 
“neuroprotection” and “neurorepair/neuroregeneration”. 
While neuroprotection refers to inhibition of the death of 
CNS parenchymal cells following trauma, neurorepair refers 
to regeneration of severed axons or sprouting of intact axons 
to innervate denervated targets. MSCs have been used for 
both of these strategies. Umbilical cord blood is a convenient 
source of HSCs and MSCs. Interestingly, transplantation of 
human umbilical cord blood (hUCB) stem cells into the rat 
spinal cord, 1 week following contusion injury, results in 
differentiation of these cells into neural cells that display the 
morphology and immunohistochemical profiles of neurons, 
oligodendrocytes and astrocytes, along with aiding in the 
remyelination of denuded axons [25]. However, it is still not 
clear which molecular factors determine the differentiation 
profile of MSCs following transplantation. Despite this unre-
solved issue, it has been reported that transplantation of 
hUCB cells can downregulate the fas/caspase-3 pathway in 
both neurons and oligodendrocytes and increase levels of 
anti-apoptotic proteins, FLICE like inhibitory protein (FLIP) 
and X-linked inhibitor of apoptosis protein (XIAP) following 
SCI in rats [26]. Recently, Dasari and colleagues have shown 
that the anti-apoptotic effects of hUCB cells, at least on cul-
tured rat cortical neurons, are mediated through upregulation 
of the Akt signalling pathway [27]. Down-regulation   
of apoptotic and up-regulation of anti-apoptotic molecules 
(Fig. 1) has also been reported by this group following trans-
plantation of allogeneic bone marrow-derived MSCs into   
the contused spinal cord in the rat [28]. These findings are 
particularly pertinent as we have shown that modulation   
of anti-apoptotic pathways, by up-regulation of the cellular 
inhibitor of apoptosis protein-2 (cIAP-2) at the lesion-site, 
can prevent secondary demyelination and oligodendrocyte 
apoptosis following SCI in the mouse leading to improve-
ment in locomotor performance [29]. 
Homing of Grafted MSCs 
  MSCs are reported to exhibit a homing capacity, which 
can be utilised to treat CNS injury. In normal healthy ani-
mals they mostly home to the bone marrow [31-33], whereas 
in animals with active inflammation, MSCs injected intrave-
nously (i.v.) preferentially migrate to the sites of inflamma-
tion [34, 35]. Acute single-dose intravenous injection of 
MSCs however, may not be an effective mechanism to de-
liver these cells to the injured CNS, as it has recently been 
shown in the rat following unilateral cortical impact TBI, 
that over 96% of the injected cells become trapped in the 
lungs and do not reach the arterial circulation [36]. Intrave-
nously injected human MSCs have been reported to localise 
to peri-lesional parenchyma following acute weight-drop 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Prevention of oligodendrocyte apoptosis by MSCs. MSC 
transplantation can reduce apoptosis of oligodendrocytes following 
CNS injury through secretion of survival factors such as IGF. This 
results in reduction of demyelination of intact axons as part of the 
secondary injury mechanisms in which oligodendrocytes retract 
their processes and then become atrophied and undergo apoptosis. 
The denuded axons subsequently degenerate and develop axonal 
swellings in which the tubulin network depolymerises. 318    Current Neuropharmacology, 2010, Vol. 8, No. 4  Azari et al. 
TBI in rats, particularly when two i.v. injections are   
performed instead of one [37, 38]. MSCs may therefore   
be used for tissue directed immunosuppression, or delivery 
of pro-survival or regenerative molecules to the lesion site, 
following CNS injury.  
Neural Differentiation of Grafted MSCs 
  It has been reported that when bone marrow-derived 
MSCs are cultured under specific conditions such as in the 
presence of EGF or BDNF, they develop neuronal mor-
phologies and begin to express neural markers such as 
Nestin, GFAP and NeuN [39]. Other investigators have used 
2% dimethylsulfoxide (DMSO) to induce MSCs to express 
neuronal markers such as NeuN, NSE and tau [40]. These 
findings have been interpreted as the ability of MSCs to dif-
ferentiate into neurons, hence suggesting a potential for their 
use in cell replacement following CNS injury and disease. 
On the other hand, more recent evidence suggests that mor-
phological differentiation of MSCs into neurons and their 
expression of neural proteins in culture, may represent arte-
facts of specific culture conditions such as serum withdrawal 
that cause F-Actin retraction and cytoplasmic collapse rather 
than neurite extension [41]. Nevertheless, Tondreau and col-
leagues have recently found significant upregulation of neu-
ral genes and downregulation of chondrogenic, osteogenic, 
adipogenic and myogenic genes in neurally differentiated 
MSCs as demonstrated by microarray analysis [42]. 
  Even though expression of the dopaminergic neuronal 
marker, tyrosine hydroxylase (TH), has been reported in 
scattered MSCs engrafted into the striatum in the MPTP 
model of Parkinson’s disease [43], other investigators have 
found no evidence of neural differentiation, in spinal cord or 
brain injury [44]. Vallieres and colleagues, for instance, in-
jected GFP-expressing bone marrow cells in adult irradiated 
rats and investigated their cellular phenotypes 1-12 months 
subsequently and found that even following brain injury 
these cells remained haematopoietic and did not differentiate 
into neural cells [45]. Although MSCs can be found months 
after administration they are only found in small numbers, 
despite continued enhancement of neurological function at 
these time-points [46]. In addition, many of these MSCs 
lodge in non-CNS tissues. This suggests that improved neu-
rological outcomes may not be due to engraftment of MSCs 
at the lesion site and their differentiation into neural cells, 
but rather to secretion of soluble factors by MSCs that may 
limit cell death in the CNS or promote endogenous progeni-
tor cell proliferation [47]. This notion is supported by the 
finding that when conditioned medium from adipose MSCs 
is administered intravenously following hypoxic-ischaemic 
brain injury in neonatal rats, hippocampal and cortical cell 
death is greatly reduced enhancing locomotor recovery [14]. 
Some of the soluble factors suggested to be responsible for 
this are IGF, VEGF, nerve growth factor (NGF), and hepato-
cyte growth factor (HGF) [48] (Fig. 2A). In summary, the 
issue of neural and/or neuronal differentiation of MSCs re-
mains controversial and has been reviewed in more detail 
elsewhere [49]. 
Pre-transplantation Genetic Engineering of MSCs  
  A viable strategy to further enhance soluble factor pro-
duction by MSCs is genetic modification. In a recent report, 
MSCs that overexpressed the HSC growth factors, GM-CSF 
and stem cell factor (SCF), were shown to promote the en-
graftment of co-transplanted cord blood HSCs in non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) 
mice [50]. MSCs have been genetically modified to produce 
a wide variety of neurotrophic factors including neurotro-
phin-3 (NT-3), BDNF, and NGF, followed by transplantation 
into the site of spinal cord lesion. MSCs, genetically modi-
fied to overexpress NT-3, can promote axonal growth in the 
corticospinal tract following SCI [51]. Robust promotion of 
rubrospinal, vestibulospinal, and reticulospinal tract axonal 
regeneration, as shown by neuronal tracing methods, is also 
possible in the chronically injured spinal cord when BDNF is 
delivered by MSCs four weeks following hemisection injury 
[52]. When BDNF-producing MSCs are transplanted into the 
site of rubrospinal tract ablation [18] or lateral funiculus le-
sions [53] in the adult rat spinal cord, they not only reduce 
neuronal loss in the red nucleus, but also promote axonal 
regrowth and lead to locomotor recovery (Fig. 2B). 
  Furthermore, when human MSCs that are modified to 
express BDNF by transfection with an adenovirus vector [54, 
55], are transplanted into rats with transient middle cerebral 
artery occlusion (MCAO), they can cause improved recovery 
from ischaemia after 7-14 days, and a reduction in apoptotic 
cell numbers in the ischaemic penumbra. Moreover, MSCs 
that overexpress BDNF and NT-3 together, not only promote 
recovery of hindlimb movement but also bladder function 
following contusion injury of the thoracic spinal cord in rats 
[56]. However, the pro-survival effects of transfected MSCs 
may be population specific depending on the neurotrophin 
they express. This notion was highlighted when MSCs ex-
pressing either NT-3 or NGF were transplanted into the in-
jured spinal cord of adult rats, and the cells expressing NT-3 
were able to prevent neuronal loss in Clarke’s nucleus 
whereas NGF expressing MSCs exhibited partial protection 
of these neurons [57]. There is evidence that the cell speci-
ficity of neurotrophins also applies to sprouting of uninjured 
neurons in the spinal cord, as sensory neurites can sprout in 
response to MSC-delivered NGF, but not when FGF2 is de-
livered by these cells [58]. The differential responses of dis-
parate neuronal populations to MSC-delivered neurotrophins 
(using constructs for overexpression) were also reported by 
Nakahara and colleagues who found that motor neurites did 
not sprout in response to NGF, NT-3 or FGF2 in the absence 
of injury while sensory neurites did, and that injury was also 
required for sensory neurites to sprout in response to BDNF 
[59]. Furthermore, severed axons located in the long de-
scending spinal tracts seem to require specific neurotrophins 
in a differential manner. Whereas rubrospinal tract fibres 
regenerate in response to administration of BDNF, due to 
their expression of the TrkB receptor [60, 61], corticospinal 
tract fibres require a combination of BDNF, NT-3 and 
GDNF, together with peripheral nerve implantation for op-
timal regrowth [62]. Therefore, the requirements of the in-
jured CNS tissue for neurotrophic factors are complex and 
cell type-specific. This mandates greater sophistication in 
terms of the design of therapeutic strategies using precise 
combinations of neurotrophic factors and specific modes of 
delivery to promote targeted neuronal regeneration. MSCs for CNS Injury  Current Neuropharmacology, 2010, Vol. 8, No. 4    319 
  The secretion of soluble pro-survival molecules by MSCs 
can be further enhanced by the trophic factors at the injury 
site as MSCs cultured with supernatants from ischaemic 
brain extracts upregulated the production of these factors 
[48]. On the other hand, factors within the injured spinal 
cord may down-regulate the expression of artificially intro-
duced BDNF in modified MSCs, as this expression has been 
reported to decrease within two weeks following injury, while 
it could be resumed following harvest and re-culture [63]. 
Therefore, the complex interaction between MSCs and the 
tissue milieu of the injured CNS remains to be fully explored. 
Immunomodulatory Effects of MSC Transplantation 
  There is evidence to suggest that MSCs are immuno- 
suppressive and that they are non-immunogenic stem cells 
that may cross HLA barriers. These cells do not initiate   
an allogeneic response in vitro and are not rapidly rejected  
in vivo [64]. This may reduce the necessity to use concomitant 
immunosuppressive treatment, as the immune system may 
not recognise the low HLA-class 1 expression on the MSCs. 
In addition, these cells secrete immunomodulatory molecules 
that arrest T cells in the G0 phase of the cell cycle that may 
also aid MSCs to escape immune recognition. MSCs can 
inhibit the pro-inflammatory cytokine interleukin-1 (IL-1), 
by secretion of IL-1 receptor antagonist (IL-1RN), and   
also inhibit production of another major pro-inflammatory 
cytokine, tumour necrosis factor-alpha (TNF), by activated 
macrophages [65]. 
  MSCs have been demonstrated to have the capacity to 
induce a variety of specific responses from the different im-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Therapeutic potential of MSCs in CNS trauma. (A) MSCs have several properties that can be harnessed for regenerative medical 
approaches such as their ability to suppress the immune system and secrete growth factors, and their capacity for being used as cellular  
vectors for therapeutic molecules such as peptides that inhibit myelin derived inhibitory factors (MAIFs) that prevent axonal regeneration. 
(B) Transplantation of MSCs, particularly ones that are genetically manipulated to secrete neurotrophic factors such as BDNF, can result in  
regeneration of injured axons and their extension into the lesion site, and reduction of the size of the spinal cord lesion. 320    Current Neuropharmacology, 2010, Vol. 8, No. 4  Azari et al. 
mune cell types (Fig. 3). In fact the anti-inflammatory prop-
erties of MSCs are sufficiently potent to have been utilised to 
treat Graft-versus-Host Disease (GvHD) in patients and there 
is also evidence to suggest that they support haematopoiesis, 
enhancing HSC transplantation [68] and immune recovery in 
vivo [69]. Comprehensive reviews of the literature on this 
subject are available [24, 66, 67]. Hilmes et al. have shown 
locomotor recovery and moderate regeneration through the 
lesion site, following moderate weight drop contusion SCI in 
the rat, after transplantation of bone marrow derived stromal 
cells. However, at 11 weeks after injury, very few of   
these cells survived in the spinal cord [46]. This finding may 
highlight the role of the host immune system in rejecting 
transplanted MSCs in the absence of immunosuppression. To 
circumvent this challenge, Tobias and colleagues employed 
an innovative strategy in which they encapsulated MSCs   
in Alginate-poly-L-ornithine to protect them from the   
host immune system and were able to obviate the need   
for immunosuppression [63]. 
Safety of MSC Transplantation 
  Human safety of MSC transplantation has been shown in 
stroke patients who also exhibited improved neurological 
function [70]. MSC transplantation also results in moderate 
improvement in nerve conduction velocities in patients with 
Metachromatic Leukodystrophy and Hurler syndrome [71]. 
The first clinical trial of MSCs in humans with SCI showed 
improved neurological function following autologous whole 
bone marrow transplantion administered to the site of injury 
in combination with intravenous GM-CSF [72]. Moreover, 
in a clinical trial using autologous MSCs injected into the 
vertebral artery the Sykova group have shown clinical im-
provement as measured by ASIA score in patients with suba-
cute SCI [73]. In addition, in a recent clinical trial, combined 
intraparenchymal and intravenous administration of MSCs 
resulted in promotion of neurological recovery in TBI pa-
tients [74]. 
Potential Caveats of MSC Transplantation 
  MSCs, by definition, have the potential to differentiate 
into osteoblasts, adipocytes and chondrocytes. Osteoblastic 
differentiation of intravenously injected MSCs has recently 
been reported in lung tumours in mice [75]. Hence, while 
there are no reports of non-neural differentiation of MSCs 
following transplantation into the injured CNS, this possibil-
ity cannot be ruled out. Being of connective tissue origin, a 
possible caveat of MSC transplantation following CNS 
trauma is that these cells could potentially contribute to the 
formation of the glial scar. While this possibility cannot be 
ruled out, Veeravalli and colleagues have recently shown 
that hUCB transplantation is associated with a reduction of 
the glial scar and an up-regulation of matrix matelloprotein-
ase-2 (MMP-2), a gelatinase that has the capacity to degrade 
scar tissue [30]. However, it is not clear to what extent the 
MSC component of hUCB is responsible for these pro-
regenerative effects. 
  Another potential caveat of therapies that are designed to 
induce sprouting and axonal regeneration, including trans-
plantation of MSCs that secrete growth factors, is that they 
may cause inappropriate sprouting that causes or enhances 
neuropathic pain [76]. At present, it is not possible to thera-
peutically induce axonal regeneration in motor axons follow-
ing CNS injury while sparing sensory axons. This is due to 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). MSCs have the capacity to modulate the immune response by reducing pro-inflammatory immune cell function and the production 
of inflammatory cytokines whilst promoting regulatory T cell proliferation and secretion of IL-4 and IL-10. MSCs for CNS Injury  Current Neuropharmacology, 2010, Vol. 8, No. 4    321 
similarities in molecular mechanisms that govern axonal 
growth in both sensory and motor neurons. 
  MSC transplantation particularly following genetic modi- 
fication is a promising strategy in treating CNS trauma.   
MSCs reside in a range of tissues that are easily accessible  
such as adipose tissue, skin, bone marrow, and even periph- 
eral blood. They can be therapeutically used in an autologous  
manner obviating the need for concomitant immunosuppres- 
sion. MSCs proliferate readily in culture and are amenable  
to genetic modification. Unlike ESC-derived cells, MSCs   
represent an adult cell population that do not give rise to   
tumours upon transplantation. Furthermore, MSCs track to  
the site of the lesion in the injured CNS where they secrete  
pro-survival factors. The combination of these properties   
of MSCs may make them ideal candidates for development  
into cell therapy strategies for neurotrauma in humans,   
particularly as delivery vehicles for therapeutic molecules. 
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